One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19.
作者信息
Amati Francesco, Dela Cruz Charles S
机构信息
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy.
Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT.
出版信息
Chest. 2021 May;159(5):1693-1695. doi: 10.1016/j.chest.2021.01.043.
Abstract
摘要
相似文献
1
One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19.
Chest. 2021 May;159(5):1693-1695. doi: 10.1016/j.chest.2021.01.043.
2
CJEM journal club: corticosteroids use for critically ill COVID-19 patients.
CJEM. 2021 Mar;23(2):162-163. doi: 10.1007/s43678-020-00056-w. Epub 2021 Jan 11.
3
[Recommendations for the study and pharmacological management in adult patients with suspected infection by SARS-CoV-2 (COVID-19)].
Rev Chilena Infectol. 2020 Dec;37(6):646-666. doi: 10.4067/S0716-10182020000600646.
4
The Right Time for Steroids in COVID-19.
Clin Infect Dis. 2021 Apr 26;72(8):1486-1487. doi: 10.1093/cid/ciaa865.
5
A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?
Ann Am Thorac Soc. 2021 Jun;18(6):1082-1083. doi: 10.1513/AnnalsATS.202101-048LE.
6
Response to letter to the editor: Rehabilitation for steroid exposed and psychologically influenced COVID-19 survivors.
J Formos Med Assoc. 2021 May;120(5):1286-1287. doi: 10.1016/j.jfma.2020.12.012. Epub 2020 Dec 11.
7
Role of corticosteroids in the treatment of COVID-19 infection.
Minerva Anestesiol. 2020 Nov;86(11):1249-1250. doi: 10.23736/S0375-9393.20.14864-8. Epub 2020 Jun 12.
8
Corticosteroids in COVID-19: one size does not fit all.
Eur Respir J. 2021 Apr 15;57(4). doi: 10.1183/13993003.00224-2021. Print 2021 Apr.
9
COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency?
J Endocrinol Invest. 2020 Jul;43(7):1035-1036. doi: 10.1007/s40618-020-01253-1. Epub 2020 Apr 16.
10
Understanding the Underlying Mechanisms of Hyponatremia in Coronavirus Disease 2019 Is Critical Since Treatment Varies Based on Etiology: Let Us Not Forget Critical Illness-Related Corticosteroid Insufficiency As the Treatment Is Very Different and Often Lifesaving!
Crit Care Med. 2021 Jul 1;49(7):e724-e725. doi: 10.1097/CCM.0000000000005006.
引用本文的文献
1
Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.
Crit Care. 2024 Jun 28;28(1):210. doi: 10.1186/s13054-024-05004-z.
2
Dexamethasone impairs the expression of antimicrobial mediators in lipopolysaccharide-activated primary macrophages by inhibiting both expression and function of interferon β.
Front Immunol. 2023 Oct 24;14:1190261. doi: 10.3389/fimmu.2023.1190261. eCollection 2023.
3
Glucocorticoid Therapy in COVID-19.
Semin Respir Crit Care Med. 2023 Feb;44(1):100-117. doi: 10.1055/s-0042-1759778. Epub 2023 Jan 16.
4
Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands.
Open Forum Infect Dis. 2022 Nov 22;9(12):ofac632. doi: 10.1093/ofid/ofac632. eCollection 2022 Dec.
5
COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study.
Ann Med. 2023 Dec;55(1):12-23. doi: 10.1080/07853890.2022.2148733.
6
From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?
Biomedicines. 2022 Oct 18;10(10):2620. doi: 10.3390/biomedicines10102620.
本文引用的文献
1
Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype.
Chest. 2021 May;159(5):1793-1802. doi: 10.1016/j.chest.2020.11.050. Epub 2020 Dec 13.
2
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
3
Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19.
Front Immunol. 2020 Aug 28;11:2145. doi: 10.3389/fimmu.2020.02145. eCollection 2020.
4
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
5
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
6
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
7
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.
Lancet Respir Med. 2020 Dec;8(12):1209-1218. doi: 10.1016/S2213-2600(20)30366-0. Epub 2020 Aug 27.
8
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
9
Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19.
Intensive Care Med. 2020 Aug;46(8):1603-1606. doi: 10.1007/s00134-020-06088-1. Epub 2020 May 15.
10
General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections.
Front Endocrinol (Lausanne). 2020 Apr 22;11:161. doi: 10.3389/fendo.2020.00161. eCollection 2020.
Zotero 插件